« Return to News | Awards & Advancement

Anne Lindblad promoted to president and CEO of EMMES

Monday, August 12, 2013 04:18 PM

EMMES has promoted executive vice president Dr. Anne Lindblad to president and chief executive officer. Lindblad replaces Dr. Donald (Don) Stablein, who has been named past president. Stablein, who joined the company in 1980, has been president/CEO since 1992. In his new role as past president, he will continue to provide project support and will be an ambassador for EMMES.

A biostatistician with experience in clinical design and project management, Lindblad became EMMES vice president in 1992 and executive vice president in 2006. During her 30 years at EMMES, she has led projects in ophthalmology, oncology, nephrology, transplantation, neurology, stroke, traumatic brain injury, dental disease and swallowing disorders. She has been a reviewer of grant and contract applications for the NIH and has chaired or worked on Data and Safety Monitoring Committees in multiple disease areas. In addition, she has been on the board of directors and president of the Society for Clinical Trials.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.